Literature DB >> 7904381

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

L C Afonso1, T M Scharton, L Q Vieira, M Wysocka, G Trinchieri, P Scott.   

Abstract

Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (TH) cells. Vaccination of BALB/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ TH1 cells. These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need to induce cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7904381     DOI: 10.1126/science.7904381

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  176 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Interleukin 12 as an adjuvant to WI-1 adhesin immunization augments delayed-type hypersensitivity, shifts the subclass distribution of immunoglobulin G antibodies, and enhances protective immunity to Blastomyces dermatitidis infection.

Authors:  M Wüthrich; B E Finkel-Jiminez; B S Klein
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 4.  Activation of skin dendritic cells by immunostimulatory DNA.

Authors:  J C Vogel; M C Udey
Journal:  Springer Semin Immunopathol       Date:  2000

5.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.

Authors:  S A Fulton; J M Johnsen; S F Wolf; D S Sieburth; W H Boom
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

9.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major.

Authors:  Z E Wang; S Zheng; D B Corry; D K Dalton; R A Seder; S L Reiner; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.